Shionogi & Co., Ltd. (OTCMKTS:SGIOF – Get Free Report) is anticipated to issue its results after the market closes on Thursday, October 29th. Analysts expect Shionogi & Co., Ltd. to post earnings of $0.2637 per share and revenue of $1.13 billion for the quarter.
Shionogi & Co., Ltd. Stock Performance
Shares of OTCMKTS:SGIOF opened at $18.00 on Thursday. Shionogi & Co., Ltd. has a 12-month low of $15.21 and a 12-month high of $26.00. The business’s fifty day simple moving average is $17.80 and its 200-day simple moving average is $18.19.
About Shionogi & Co., Ltd.
Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a focus on addressing infectious diseases and other significant unmet medical needs.
Its portfolio and development programs have included treatments for infectious diseases, central nervous system conditions, pain and other therapeutic areas. Shionogi is known for products such as Xofluza (baloxavir marboxil), an influenza treatment, and Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat bacterial infections.
See Also
- Five stocks we like better than Shionogi & Co., Ltd.
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
